Literature DB >> 8681971

Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML).

T Grötzinger1, T Sternsdorf, K Jensen, H Will.   

Abstract

Promyelocytic leukemia protein (PML) and Sp100 are transcription-regulatory proteins which colocalize in discrete nuclear dots and play a role in autoimmunity, oncogenesis and virus-host interaction. Interferons (IFNs) were shown previously to increase strongly the levels of Sp100 mRNA and protein. Here, we examined which mechanisms lead to upregulation of Sp100 gene expression and whether IFNs also increase expression of the promyelocytic leukemia (PML) gene. We found that both mRNA and protein levels of PML are also strongly upregulated by IFNs. In addition, new Sp100 and PML proteins were detected immunologically after IFN treatment of cells. Nuclear run-on analysis revealed protein-synthesis-independent, rapid IFN-enhanced transcription rates as well as synergistic activation of the Sp100 and PML genes by type-I and type-II IFNs. These data demonstrate that PML and Sp100 belong to the growing family of IFN-stimulated genes (ISGs) upregulated most likely by the transcription factor ISGF3, and indicate that IFNs also qualitatively alter the expression of these two genes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8681971     DOI: 10.1111/j.1432-1033.1996.0554z.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  54 in total

1.  Antiviral action of the tumor suppressor ARF.

Authors:  María A García; Manuel Collado; César Muñoz-Fontela; Ander Matheu; Laura Marcos-Villar; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas
Journal:  EMBO J       Date:  2006-09-07       Impact factor: 11.598

2.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

3.  Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Alexey Ivanov; Frank Rauscher; Gerd G Maul
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Sp100A is a tumor suppressor that activates p53-dependent transcription and counteracts E1A/E1B-55K-mediated transformation.

Authors:  J Berscheminski; J Brun; T Speiseder; P Wimmer; W H Ip; M Terzic; T Dobner; S Schreiner
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

5.  Sp100 isoform-specific regulation of human adenovirus 5 gene expression.

Authors:  Julia Berscheminski; Peter Wimmer; Juliane Brun; Wing Hang Ip; Peter Groitl; Tim Horlacher; Ellis Jaffray; Ron T Hay; Thomas Dobner; Sabrina Schreiner
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

6.  PUM1 is a biphasic negative regulator of innate immunity genes by suppressing LGP2.

Authors:  Yonghong Liu; Linlin Qu; Yuanyuan Liu; Bernard Roizman; Grace Guoying Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

7.  The SP100 component of ND10 enhances accumulation of PML and suppresses replication and the assembly of HSV replication compartments.

Authors:  Pei Xu; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

8.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

9.  Components of nuclear domain 10 bodies regulate varicella-zoster virus replication.

Authors:  Christos A Kyratsous; Saul J Silverstein
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

10.  MORC3, a Component of PML Nuclear Bodies, Has a Role in Restricting Herpes Simplex Virus 1 and Human Cytomegalovirus.

Authors:  Elizabeth Sloan; Anne Orr; Roger D Everett
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.